Nanoparticles targeting mechanisms in cancer therapy: current limitations and emerging solutions

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Pharmacology

Background:

• The 'Magic Bullet' concept by Paul Ehrlich proposed targeted molecular therapy over a century ago.
• Nanoparticles present an opportunity to modify drug pharmacokinetics for improved pharmacodynamics.
• Unique physicochemical properties of nanoparticles at the nanoscale necessitate new pharmacokinetic models.

Purpose of the Study:

• To discuss the concept of targeting tumor cells using nanoparticles.
• To identify limitations hindering the clinical application of nanoparticle-based drug delivery.
• To explore promising solutions to overcome these limitations.

Main Methods:

• Review of existing literature on nanoparticle targeting in cancer therapy.
• Analysis of in vitro and animal models for nanoparticle efficacy.
• Discussion of challenges in translating preclinical findings to human clinical settings.

Main Results:

• Nanoparticles can alter drug pharmacokinetics, potentially improving therapeutic outcomes.
• Current nanoparticle targeting strategies often fail to accurately mimic the human tumor microenvironment.
• Significant discrepancies exist between preclinical results and clinical efficacy.

Conclusions:

• Nanoparticle-based drug targeting holds great promise but faces significant hurdles for clinical translation.
• Developing models that accurately reflect the human tumor microenvironment is crucial for advancing nanoparticle therapy.
• Further research is needed to bridge the gap between experimental findings and successful clinical applications.